Vanguard Medica was advised by McKenna & Co on the signing of a license agreement for kidney disease treatment with British Technology Group, advised by its in-house legal team. The firm also advised on the collaboration of Vanguard Medica with Smithkline Beecham, advised by the in-house legal team, on an anti-migraine drug. Vanguard Medica was also advised by McKennas on the u2m investment by Allstate Venture Capital, advised in-house, as an interim financing round.